Company
Hutchmed
Hutchmed has 23 drugs tracked on RxWires: 3 in Phase 3, 3 in Phase 2/3, 3 in Phase 2, 8 in Phase 1/2, 6 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| HMPL-306 tablet | Phase 3 | Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation |
| Savolitinib | Phase 3 | Non-small Cell Lung Cancer |
| HMPL-760 | Phase 3 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| fruquintinib+sintilimab | Phase 2/3 | Advanced Renal Cell Carcinoma |
| Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine | Phase 2/3 | Metastatic Pancreatic Cancer |
| HMPL-523(300mg PO QD) | Phase 2/3 | Warm Antibody Autoimmune Hemolytic Anemia |
| tazemetostat | Phase 2 | Relapsed/Refractory Lymphoma |
| HMPL-760 planned dose 1 | Phase 2 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| Tislelizumab & Fruquintinib | Phase 2 | Metastatic Colorectal Cancer |
| Surufatinib in combination with Gemcitabine | Phase 1/2 | Solid Tumor |
| surufatinib | Phase 1/2 | Tumors |
| Surufatinib and Tislelizumab _ Part 1 | Phase 1/2 | Metastatic Solid Tumor |
| Pamiparib | Phase 1/2 | Ovarian Cancer |
| HMPL-A830 | Phase 1/2 | Solid Tumor, Adult |
| HMPL-A251 | Phase 1/2 | Solid Tumors, Adult |
| HMPL-A580 | Phase 1/2 | Solid Tumors, Adult |
| Fruquintinib in Combination with Sintilimab | Phase 1/2 | Advanced Solid Tumor |
| Fruquintinib | Phase 1 | Hepatic Impairment |
| 100 µCi [14C] HMPL-306 | Phase 1 | Mass Balance Study |
| HMPL-295S1 with dose escalation stage of 5mg up to 200mg, then expansion stage with recommended dose of therapeutic cycle of 28 days . | Phase 1 | Advanced Malignant Solid Tumors |
| Itraconazole 200 mg | Phase 1 | Relapsed or Refractory Lymphoma |
| HMPL-453 with Itraconazole | Phase 1 | Health, Subjective |
| HMPL-453 | Phase 1 | Mass Balance Study |
Latest
Follow Hutchmed on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.